REG - Yourgene Health PLC - Appointment of Joint Broker

Yourgene HealthAnnouncement

29/07/2020 12:05

RNS Number : 4965U
  
Yourgene Health PLC
  
29 July 2020
  
 

 
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
 
Appointment of Joint Broker
 
Manchester, UK - 29 July 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces the appointment of Nplus1 Singer Advisory LLP ("N+1 Singer") as joint broker with immediate effect.
 
Cairn Financial Advisors LLP will continue as the Company's nominated adviser and Stifel Nicolaus Europe Limited will continue as the Company's joint broker. 
 
 



Yourgene Health plc
Lyn Rees, Chief Executive Officer


Tel: +44 (0)161 669 8122
investors@yourgene-health.com  




Barry Hextall, Chief Financial Officer


 




Joanne Cross, Director of Marketing


 




 


 




 


 




Cairn Financial Advisers LLP (NOMAD)


Tel: +44 (0)20 7213 0880




Liam Murray / James Caithie / Ludovico Lazzaretti


















N+1 Singer (Joint Corporate Broker)


Tel: +44 (0)207 496 3000




Aubrey Powell / Tom Salvesen / George Tzimas


 




 


 




Stifel Nicolaus Europe Limited (Joint Corporate Broker)


Tel: +44 (0)20 7710 7600




Nicholas Moore / Matthew Blawat / Ben Maddison


 




 


 




 


 




Walbrook PR Ltd (Media and Investor Relations)


Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 




Paul McManus / Lianne Cawthorne


Mob: 07980 541 893 / Mob: 07584 391 303  




 


 


 



 
 
About Yourgene Health plc
Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 
 
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and precision medicine. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
 
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.
 
Yourgene is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
APPBGGDRIUDDGGC